Head and neck cancer trial pulled before it began

NCT ID NCT01326468

Terminated Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study aimed to test the safety of adding the drug Temsirolimus (Torisel) to standard chemoradiotherapy for people with advanced head and neck cancer. The goal was to find a safe dose of Temsirolimus when given alongside radiation and other chemotherapy drugs like Cetuximab (Erbitux). However, the study was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Temsirolimus (Torisel) and Cetuximab (Erbitux)
What this could lead to: If it had worked, this could have pointed toward a more effective treatment for advanced head and neck cancer by adding Temsirolimus to standard therapy.
What could go wrong: The trial was withdrawn before any patients were enrolled, so no results are available. It is unknown whether the combination would have been safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.